In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.
j.yeh2 May 2022